Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab

Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab

Objective. To evaluate B-cell counts in circulation of SS patients prior to initiation and one year after completion of RTM therapy.Subjects and methods. The study included 71 patients. Median follow up was 13,2±2,0 months (11-18 Mo.). Average cumulative RTM dose during the follow up period was 1,43...

Full description

Bibliographic Details
Main Authors: L. P. Ananieva, L. A. Garzanova, O. V. Desinova, O. A. Koneva, M. N. Starovoytova, O. B. Ovsyannikova, A. P. Aleksankn, S. I. Glukhova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2020-09-01
Series:Научно-практическая ревматология
Subjects:
systemic scleroderma
anti-в-cell therapy
rituximab
Online Access:https://rsp.mediar-press.net/rsp/article/view/2927

Similar Items

Similar Items